Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo To File ANDA For Lanoxin Elixir, Requests Two-Years For Approval

Executive Summary

GlaxoSmithKline plans to file an ANDA for Lanoxin Elixir using the tablet formulation of its cardiac drug Lanoxin (digoxin) as its reference drug.
Advertisement

Related Content

Digoxin Timelines: Unapproved Tablets Can Remain 30 Days, Elixirs Two Years
Digoxin Timelines: Unapproved Tablets Can Remain 30 Days, Elixirs Two Years
Digoxin Marketing Rule Should Postpone Effective Date Two Years - Jerome
Bertek/FDA digoxin settlement
Digoxin marketing requirements
Digoxin marketing requirements
Levothyroxine NDAs May Be Refused Filing After First Product Approval - FDA
Advertisement
UsernamePublicRestriction

Register

PS037658

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel